Segment Information and Concentration (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 2,769,100	$ 2,585,500	$ 7,899,900	$ 8,373,400
Income (Loss) from Operations			4,515,300	6,863,600
Bioprocessing Systems
Revenues	452,500	424,200	1,134,000	1,015,600
Foreign Sales	241,900	242,900	648,100	478,700
Income (Loss) from Operations	(1,200,000)	(2,105,500)	(4,094,700)	(5,972,600)
Assets	4,697,900	5,101,300	4,697,900	5,101,300
Long-lived Asset Expenditures	900	11,700	3,200	92,700
Depreciation and Amortization	166,200	167,500	500,700	502,300
Benchtop Laboratory Equipment
Revenues	2,316,600	2,161,300	6,765,900	7,357,800
Foreign Sales	562,000	625,000	1,779,100	2,204,800
Income (Loss) from Operations	258,700	73,600	546,000	555,200
Assets	6,114,600	7,137,200	6,144,600	7,137,200
Long-lived Asset Expenditures	2,900	0	72,800	25,200
Depreciation and Amortization	21,900	20,700	64,700	64,400
Corporate
Revenues	0	0	0	0
Foreign Sales		0	0
Income (Loss) from Operations	(317,300)	(193,500)	(1,135,600)	(1,501,800)
Assets	2,464,300	809,600	2,464,300	809,600
Long-lived Asset Expenditures	0	0	0	0
Depreciation and Amortization	0	0	0	0
Consolidated
Revenues	2,769,100	2,585,500	7,899,900	8,373,400
Foreign Sales	803,900	867,900	2,427,200	2,683,500
Income (Loss) from Operations	(1,258,600)	(2,225,400)	(4,684,300)	(6,919,200)
Assets	13,306,800	13,048,100	13,306,800	13,048,100
Long-lived Asset Expenditures	3,800	11,700	76,000	117,900
Depreciation and Amortization	$ 188,100	$ 188,200	$ 565,400	$ 566,700